医学
化疗
新辅助治疗
养生
肿瘤科
胰腺癌
内科学
佐剂
胰腺切除术
癌症
化疗方案
胰腺
乳腺癌
作者
Elizabeth M. Gleeson,Natasha Leigh,Benjamin Golas,Deepa Magge,Umut Sarpel,Spiros P. Hiotis,Daniel M. Labow,Sofya Pintova,Noah A. Cohen
出处
期刊:Pancreas
[Ovid Technologies (Wolters Kluwer)]
日期:2021-09-01
卷期号:50 (8): 1163-1168
标识
DOI:10.1097/mpa.0000000000001881
摘要
Currently, there is no guidance for optimal adjuvant chemotherapy selection after pancreatectomy with a partial or poor response to neoadjuvant therapy. This study seeks to describe an institution's practice patterns of adjuvant chemotherapy selection after neoadjuvant therapy.Patients at a single institution receiving neoadjuvant chemotherapy followed by pancreatectomy for pancreatic cancer were reviewed. Patients enrolled in trials or without follow-up were excluded. Types of chemotherapy, the College of American Pathologists pathologic tumor response, and medical oncology plans were recorded.Forty-one patients met inclusion criteria. Pathologic review of treatment effect demonstrated that 3 patients (7.3%) had complete pathologic response, 3 (7.3%) had near complete pathologic response, 16 (39%) had partial response, and 14 (34.1%) had poor/no response to neoadjuvant chemotherapy. Fourteen of the 30 patients with partial or poor response (46.7%) received an alternate adjuvant regimen. Pathologic response to neoadjuvant chemotherapy specifically guided therapy in 11 (30.5%) patients.Despite 73.1% of patients with partial or poor response to neoadjuvant chemotherapy, only 46.7% received a different adjuvant regimen. Medical oncologists infrequently considered treatment effect when choosing adjuvant therapy. Pathologic response to neoadjuvant chemotherapy should be considered when selecting adjuvant chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI